Bio-surgical medical device company LifeBond said today it closed a $27 million Series D equity round, with funds slated to support its flagship LifeSeal surgical sealant. Funds came from Pitango Venture Capital, Adams Street Partners, Sino Biopharmaceutical Ltd and existing investors, the company said. “LifeSeal is a novel product that addresses an urgent unmet need […]
Regenerative Medicine
Acelity announced Q2 earnings, beats 2014
Wound care and regenerative medicine company Acelity reported its Q2 earnings this week, beating its revenue and sales marks the same quarter last year. The San Antonio, Texas-based company said it brought in $461.6 million this quarter, beating last year’s revenue by a meager 0.5%. The company significantly pared losses, bringing them down to $17.6 […]
Integra LifeSciences picks up TEI Biosciences, TEI Medical for $312m
Integra LifeSciences (NSDQ:IART) said yesterday that it agreed to acquire TEI Biosciences and sister company TEI Medical for $312 million in cash in a bid to expand its footprint in reconstructive surgery and regenerative wound care. The deal, expected to close during the 3rd quarter, brings TEI’s PriMatrix dermal repair scaffold and a 125-member sales force under the […]
TissueTech raises another $15m
TissueTech said today that it added another $15 million to its coffers, led by prior backers River Cities Capital Funds and Ballast Point Ventures. Doral, Fla.-based TissueTech makes amniotic membrane- and umbilical cord-based products designed to treat ocular surface diseases (its Bio-Tissue subsidiary) and musculoskeletal conditions and wound care (its Amniox Medical business). The company raised […]
Organogenesis lauds Apligraf CE data
Organogenesis said today that a comparative effectiveness analysis of its Apligraf skin substitute has shown improved outcomes over competitor MiMedx‘s (NSDQ:MDXG) Epifix. The study, published this week in Wound Repair & Regeneration, examined healing rates of patients with diabetic foot ulcers treated either with Apligraf or Epifix. Data from the 218-patient, 99-center retrospective study showed a 97% […]
Admedus releases new CardioCel scaffold in U.S.
InVivo reports mixed results in spinal scaffold trial
InVivo Therapeutics, ex-CEO Reynolds escape shareholders’ lawsuit
OvaScience shares up on 1st birth after its fertility treatment
(Reuters) — Shares in OvaScience (NSDQ:OVAS) were up 8% at 1 point today after the company announced the 1st birth of baby resulting from its experimental Augment fertility treatment.